Balchem Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 5/6
Balchem verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 11.7%, während die Gewinne der Branche Chemicals jährlich um rückläufig und zwar um 3.8%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 5.6%. Die Eigenkapitalrendite von Balchem beträgt 12.6% und die Nettomargen betragen 15.1%.
Wichtige Informationen
11.68%
Wachstumsrate der Gewinne
11.61%
EPS-Wachstumsrate
| Chemicals Wachstum der Industrie | 12.93% |
| Wachstumsrate der Einnahmen | 5.60% |
| Eigenkapitalrendite | 12.62% |
| Netto-Marge | 15.14% |
| Letzte Ertragsaktualisierung | 30 Jun 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Narrative-Update • Aug 04
BCPC: Record Earnings And Buybacks Will Support Strong Future Returns
Analysts have raised their price target for Balchem to $207.00 from $200.75, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for Balchem Balchem reported record Q2 2026 net sales, net earnings, and adjusted EBITDA, with revenue at US$284.0 million.Seeking Alpha • Aug 02
Balchem: It's A Buy From Me After Posting Strong Q2 Results
Summary Balchem Corporation posted Q2 results, with EPS of $1.49 beating estimates by $0.07, while surpassing the consensus by $15M and was up 11% YoY. All areas of the business posted impressive results, as the minimum revenue growth for a segment was 8.9%, while the peak was 15% in Animal Nutrition & Health. The stock appears to be trading for a ~9% discount to its fair value right now based on my FCF valuation model. Read the full article on Seeking AlphaNarrative-Update • Jun 26
BCPC: Share Repurchases And Strong Margins Will Support Future Returns
Analysts have lifted their Balchem fair value estimate from $191 to about $200.75, citing updates to their models that include revised assumptions for revenue growth, profit margins, the discount rate, and Balchem's future P/E multiple. What’s in the News for Balchem Balchem reported that from January 1, 2026 to March 31, 2026, the company repurchased 89,880 shares, representing 0.28% of its shares, for US$14.92 million under its existing buyback program.
Neues Narrative • Mar 13
Long-Term Nutrition And Health Trends Will Support Stronger Margins And Earnings Potential
Catalysts About Balchem Balchem supplies specialty nutrients and ingredients for human, animal and plant health, along with performance gases and related solutions. What are the underlying business or industry changes driving this perspective?
Neues Narrative • Feb 26
Encapsulation Investments And International Expansion Will Shape Balanced Future For Nutrition Specialist
Catalysts About Balchem Balchem produces specialty nutrition and ingredient solutions for human, animal and plant health, along with performance gases. What are the underlying business or industry changes driving this perspective?Narrative-Update • Feb 17
BCPC: Dividend Increase And Buyback Program Will Support Steady Future Returns
Analysts kept their Balchem fair value estimate broadly steady at $191, pointing to only very small tweaks in assumptions such as discount rate, long term revenue growth, profit margin and future P/E as the basis for maintaining their target level. What's in the News On December 9, 2025, Balchem Corporation's Board of Directors declared an annual dividend of $0.96 per share, payable on January 20, 2026, to stockholders of record as of December 23, 2025.Analyseartikel • Feb 15
If EPS Growth Is Important To You, Balchem (NASDAQ:BCPC) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Narrative-Update • Feb 03
BCPC: Share Repurchases And Higher Dividend Will Support Attractive Future Returns
Analysts have maintained their fair value estimate for Balchem at US$191. They have made only minimal adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions, indicating that their overall view on the stock's valuation drivers remains essentially unchanged.Analyseartikel • Feb 01
Is Now An Opportune Moment To Examine Balchem Corporation (NASDAQ:BCPC)?
Balchem Corporation ( NASDAQ:BCPC ), is not the largest company out there, but it saw a decent share price growth of...Narrative-Update • Jan 20
BCPC: Share Repurchases And Rising Dividend Will Support Attractive Future Returns
Analysts have maintained their Balchem fair value estimate at US$191, with only small tweaks to the discount rate, revenue growth, profit margin, and forward P/E assumptions. This reflects a largely unchanged view on the stock's risk and earnings profile.Narrative-Update • Jan 05
BCPC: Share Repurchases And Dividend Increases Will Support Attractive Future Returns
Analysts kept their fair value estimate for Balchem steady at US$191, pointing to only very small model tweaks in the discount rate, revenue growth, margin and forward P/E assumptions rather than any change in their overall view of the company. What's in the News Balchem Corporation announced a share repurchase program authorizing the company to buy back up to 4,000,000 shares, with no expiration date on the program (Key Developments).Narrative-Update • Dec 20
BCPC: Share Repurchases And Dividend Increases Will Drive Attractive Future Returns
Analysts have maintained their price target on Balchem at approximately $191.00. This reflects only marginal tweaks to underlying assumptions such as discount rate, revenue growth, and profit margin, rather than a material change in their outlook.Narrative-Update • Dec 06
BCPC: Share Repurchases Will Support Attractive Long Term Return Potential
Analysts have lowered their price target on Balchem by approximately $9 to about $191 per share, reflecting more cautious assumptions around revenue growth and profit margins, even though long term valuation multiples are slightly higher. What's in the News Completed a long running share repurchase program, buying back a total of 3,475,622 shares, or about 12.76% of shares outstanding, for approximately $190.58 million since the authorization began in 1999 (Key Developments) During the most recent quarter from July 1, 2025 to September 30, 2025, repurchased 95,760 shares, roughly 0.3% of shares outstanding, for $15.42 million as the final tranche under the existing buyback plan (Key Developments) Valuation Changes The Fair Value Estimate has fallen modestly from about $200.33 to $191.00 per share, reflecting a slightly more conservative outlook.Analyseartikel • Dec 01
Balchem (NASDAQ:BCPC) Is Experiencing Growth In Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Analyseartikel • Oct 10
Some Shareholders Feeling Restless Over Balchem Corporation's (NASDAQ:BCPC) P/E Ratio
Balchem Corporation's ( NASDAQ:BCPC ) price-to-earnings (or "P/E") ratio of 31.9x might make it look like a strong sell...Analyseartikel • Sep 26
Balchem (NASDAQ:BCPC) Could Easily Take On More Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Aug 26
Estimating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Balchem fair value estimate is US$174 With US$162 share price...Seeking Alpha • Oct 28
Balchem's Q3 Shows Record Earnings And Valuation Pressure
Summary Balchem Corporation shows strong long-term growth potential in high-margin segments and product innovation, but faces challenges in Animal Nutrition & Health and rising costs. Balchem's financial momentum in Q3 2024 includes record earnings, improved margins, and significant debt reduction, despite missing revenue estimates. BCPC stock's high P/E ratio of 39.82x suggests big market expectations, but the current valuation may be too high given existing challenges. I rate Balchem as a “Hold” due to high valuation, operational challenges, and potential seasonal slowdown, advising cautious investors to wait for a better entry point. Read the full article on Seeking Alpha
Neues Narrative • Aug 29
Innovating In Nutrition And Health Sectors Drives Strong Financial Growth And Market Expansion
Launch of Optifolin+ in the nutrition segment and strong Human Nutrition & Health sales indicate potential for market share expansion and sustained revenue growth.Seeking Alpha • May 10
Balchem: A Tale Of Two Businesses
Summary Balchem Corporation's Q1 2024 earnings surpassed expectations, but the company's full-year bottom-line expansion could be slower than what it achieved for the first quarter. The Human Nutrition & Health segment is riding on the supplements market's growth, while the Animal Nutrition & Health segment is encountering stiff competition in the European animal feed market. It is a tale of two businesses for BCPC, which implies that the stock warrants a Neutral or Hold rating. Read the full article on Seeking AlphaSeeking Alpha • Feb 21
Balchem: Potential Turnaround Is In The Price
Summary Balchem registered a -2.5% top-line miss for the fourth quarter of 2023, which is attributable to the underperformance of its Animal Nutrition business. BCPC is well-positioned to achieve positive top line and earnings expansion in the current year, but I deem the stock's valuations to be fair. The Company continues to be rated as a Hold, as my opinion is that the expected 2024 turnaround for BCPC is priced in. Read the full article on Seeking AlphaAufschlüsselung der Einnahmen und Ausgaben
Aufschlüsselung der Einnahmen und Ausgaben
Wie Balchem Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 26 | 1,086 | 164 | 152 | 20 |
| 31 Mar 26 | 1,057 | 158 | 150 | 20 |
| 31 Dec 25 | 1,037 | 155 | 143 | 19 |
| 30 Sep 25 | 1,014 | 149 | 140 | 18 |
| 30 Jun 25 | 986 | 143 | 137 | 18 |
| 31 Mar 25 | 965 | 137 | 133 | 17 |
| 31 Dec 24 | 954 | 128 | 136 | 17 |
| 30 Sep 24 | 942 | 122 | 144 | 16 |
| 30 Jun 24 | 932 | 117 | 139 | 16 |
| 31 Mar 24 | 930 | 115 | 131 | 16 |
| 31 Dec 23 | 922 | 109 | 120 | 15 |
| 30 Sep 23 | 926 | 103 | 117 | 14 |
| 30 Jun 23 | 941 | 99 | 122 | 13 |
| 31 Mar 23 | 946 | 99 | 126 | 12 |
| 31 Dec 22 | 942 | 105 | 121 | 12 |
| 30 Sep 22 | 923 | 109 | 116 | 14 |
| 30 Jun 22 | 877 | 109 | 109 | 14 |
| 31 Mar 22 | 842 | 102 | 107 | 14 |
| 31 Dec 21 | 799 | 96 | 102 | 14 |
| 30 Sep 21 | 767 | 93 | 100 | 11 |
| 30 Jun 21 | 744 | 90 | 100 | 11 |
| 31 Mar 21 | 715 | 88 | 99 | 10 |
| 31 Dec 20 | 704 | 85 | 102 | 10 |
| 30 Sep 20 | 689 | 83 | 104 | 11 |
| 30 Jun 20 | 673 | 82 | 104 | 11 |
| 31 Mar 20 | 661 | 81 | 102 | 11 |
| 31 Dec 19 | 644 | 80 | 95 | 11 |
| 30 Sep 19 | 641 | 80 | 89 | 12 |
| 30 Jun 19 | 637 | 78 | 84 | 12 |
| 31 Mar 19 | 639 | 78 | 82 | 12 |
| 31 Dec 18 | 644 | 79 | 84 | 12 |
| 30 Sep 18 | 639 | 100 | 83 | 11 |
| 30 Jun 18 | 635 | 97 | 84 | 11 |
| 31 Mar 18 | 618 | 94 | 81 | 10 |
| 31 Dec 17 | 595 | 90 | 81 | 9 |
| 30 Sep 17 | 576 | 64 | 82 | 9 |
| 30 Jun 17 | 564 | 62 | 82 | 8 |
| 31 Mar 17 | 556 | 60 | 82 | 7 |
| 31 Dec 16 | 553 | 56 | 83 | 7 |
| 30 Sep 16 | 545 | 56 | 77 | 7 |
| 30 Jun 16 | 547 | 56 | 76 | 7 |
| 31 Mar 16 | 543 | 56 | 72 | 6 |
| 31 Dec 15 | 552 | 60 | 68 | 6 |
| 30 Sep 15 | 582 | 63 | 71 | 6 |
Qualität der Erträge: BCPC hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: BCPCDie aktuellen Gewinnspannen (15.1%) sind höher als im letzten Jahr (14.5%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: BCPCIn den letzten 5 Jahren sind die Gewinne von 11.7% jährlich gestiegen.
Beschleunigtes Wachstum: BCPCDas Gewinnwachstum des Unternehmens im letzten Jahr (15.2%) übertrifft seinen 5-Jahres-Durchschnitt (11.7% pro Jahr).
Erträge im Vergleich zur Industrie: BCPC Das Gewinnwachstum im vergangenen Jahr (15.2%) übertraf das der Branche Chemicals -4% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: BCPCDie Eigenkapitalrendite des Unternehmens (12.6%) wird als niedrig angesehen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/05 00:09 |
| Aktienkurs zum Tagesende | 2026/08/05 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Balchem Corporation wird von 9 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Robert Labick | CJS Securities, Inc. |
| Timothy Ramey | D.A. Davidson & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |